New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:22 EDTRXIIRXi Pharmaceuticals announces results of Phase 1 RXI-109 study
RXi Pharmaceuticals announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects. This drug candidate is a highly selective CTGF targeting sd-rxRNA compound that is administered through intradermal injections to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. In this study, 15 volunteers divided over 5 cohorts received single intradermal injections in a dose escalating manner, and blood was drawn at various time points to evaluate the distribution of the drug beyond the injected tissue, into the systemic circulation. Previous primate toxicology work with RXI-109 had shown that the peak blood levels obtained after intradermal injections with 10 mg/kg were approximately 3.5% of the peak levels obtained after intravenous injections with the same dose. With the different doses in the primate study, the dermal and systemic side effects in the animals were minimal. The calculated relative systemic exposure in the 15 volunteers was between 1 and 7% which is very similar to the systemic exposure in primates. As reported earlier, the drug was very well tolerated in all volunteers tested.
News For RXII From The Last 14 Days
Check below for free stories on RXII the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:08 EDTRXIIRXi Pharmaceuticals granted new patents in U.S., Europe and Japan
Subscribe for More Information
September 11, 2014
09:20 EDTRXIIRXi Pharmaceuticals weakness a buying opportunity, says H.C. Wainwright
Subscribe for More Information
07:10 EDTRXIIRXi Pharmaceuticals provides update on dermatology and ophtalmology franchises
Subscribe for More Information
September 10, 2014
12:27 EDTRXIIRXi says study suggests delayed treatment appears better than early treatment
Subscribe for More Information
12:14 EDTRXIIRXi Pharmaceuticals drops 30% while presenting at conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use